FDA
-
-
-
-
-
-
-
Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results
-
-
-
-
-
-
-
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
-
-
-
-
-
-
-
Verrica begins phase 3 trial for common warts treatment
-
-
-
-
-
-
-
Lucid Capital Markets Starts Verrica Pharmaceuticals (VRCA) at Buy
-
-
-
-
-
-
-
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
-
-
-
-
-
-
-
Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Comm
-
-
-
-
-
-
-
Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors
-
326,538 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

